Oramed Pharmaceuticals Inc. (ORMP) Financial Statements (2024 and earlier)

Company Profile

Business Address 1185 AVENUE OF THE AMERICAS, 3RD FLOOR
NEW YORK, NY 10036
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2023
MRQ
12/31/2022
8/31/2021
8/31/2020
8/31/2019
8/31/2018
8/31/2017
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments44,20783,09622,5947,0309,5886,829
Cash and cash equivalents40,46477,24519,2963,3294,9963,969
Short-term investments3,7435,8513,2983,7014,5922,860
Restricted cash and investments      16
Deposits current assets111,51311,04411,06025,25220,87513,293
Other undisclosed current assets1,3891,1976,8571,042574159
Total current assets:157,10995,33740,51133,32431,03720,297
Noncurrent Assets
Operating lease, right-of-use asset98753375 
Property, plant and equipment81539799241718
Long-term investments and receivables2,70019,2353,9281,2955,5701
Long-term investments2,70019,2353,9281,2955,5701
Deposits noncurrent assets      
Other undisclosed noncurrent assets3112,497202010,77318,396
Total noncurrent assets:4,53332,6624,1221,33916,36018,415
TOTAL ASSETS:161,642127,99944,63334,66347,39738,712
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:4,1583,7921,6992,5412,0582,716
Accrued liabilities 5     
Other undisclosed accounts payable and accrued liabilities4,1533,7921,6992,5412,0582,716
Deferred revenue   2,7032,703
Debt      
Deferred revenue and credits2,449
Due to related parties154906446 
Other liabilities      
Other undisclosed current liabilities1,5872,83344 2,449 
Total current liabilities:5,7466,6794,5365,3084,5535,165
Noncurrent Liabilities
Long-term debt and lease obligation:  40331   
Liabilities, other than long-term debt, including:4,6474,2447,1879,96234414,309
Deferred revenue and credits13,837
Accounts payable and accrued liabilities  823    
Deferred revenue4,000 6,9479,658
Liability for uncertainty in income taxes   11111111
Liability, pension and other postretirement and postemployment benefits   18222018
Other liabilities   211271313443
Operating lease, liability64740331 
Other undisclosed liabilities, other than long-term debt  3,421    
Other undisclosed noncurrent liabilities93156  11,388 
Total noncurrent liabilities:4,7404,8037,2189,96211,73214,309
Total liabilities:10,48611,48211,75415,27016,28519,474
Equity
Equity, attributable to parent151,812115,77332,87919,39331,11219,238
Common stock476424284208207163
Additional paid in capital314,417230,201125,209100,28899,42675,170
Accumulated other comprehensive income     702401
Accumulated deficit(163,081)(114,852)(92,614)(81,103)(69,223)(56,496)
Equity, attributable to noncontrolling interest(656)744    
Total equity:151,156116,51732,87919,39331,11219,238
TOTAL LIABILITIES AND EQUITY:161,642127,99944,63334,66347,39738,712

Income Statement (P&L) ($ in thousands)

9/30/2023
TTM
12/31/2022
8/31/2021
8/31/2020
8/31/2019
8/31/2018
8/31/2017
Revenues2,7032,7032,7102,7032,4492,456
Revenue, net2,194
Cost of revenue    (90) (187)
Gross profit:2,7032,7032,7102,6132,4492,269
Operating expenses(43,301)(26,926)(14,467)(17,244)(16,062)(13,040)
Other undisclosed operating income    86 
Operating loss:(40,598)(24,223)(11,757)(14,631)(13,527)(10,771)
Nonoperating income (expense)1,550(195)246576800691
Gain (loss), foreign currency transaction, before tax1,550(187)    
Other nonoperating income (expense)  (8)246576800691
Interest and debt expense      
Loss from continuing operations before equity method investments, income taxes:(39,048)(24,418)(11,511)(14,055)(12,727)(10,080)
Other undisclosed loss from continuing operations before income taxes      
Loss from continuing operations before income taxes:(39,048)(24,418)(11,511)(14,055)(12,727)(10,080)
Income tax expense (100)  (300) (400)
Other undisclosed income from continuing operations39,248     
Income (loss) from continuing operations:100(24,418)(11,511)(14,355)(12,727)(10,480)
Loss before gain (loss) on sale of properties:(24,418)(11,511)(14,355)(12,727)(10,480)
Other undisclosed net income (loss)(37,864)1,429    
Net loss:(37,764)(22,989)(11,511)(14,355)(12,727)(10,480)
Net income attributable to noncontrolling interest1,20320,743    
Other undisclosed net loss attributable to parent  (20,743)    
Net loss attributable to parent:(36,561)(22,989)(11,511)(14,355)(12,727)(10,480)
Other undisclosed net income available to common stockholders, basic  45,978    
Net income (loss) available to common stockholders, diluted:(36,561)22,989(11,511)(14,355)(12,727)(10,480)

Comprehensive Income ($ in thousands)

9/30/2023
TTM
12/31/2022
8/31/2021
8/31/2020
8/31/2019
8/31/2018
8/31/2017
Net loss:(37,764)(22,989)(11,511)(14,355)(12,727)(10,480)
Other comprehensive income     301295
Comprehensive loss:(37,764)(22,989)(11,511)(14,355)(12,426)(10,185)
Comprehensive income, net of tax, attributable to noncontrolling interest 751    
Other undisclosed comprehensive income (loss), net of tax, attributable to parent 44,476    
Comprehensive income (loss), net of tax, attributable to parent:(37,764)22,238(11,511)(14,355)(12,426)(10,185)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: